← All stocks

Humacyte, Inc.

HUMA Net buying
CIK 0001818382 #3976 in the set updated 17 Sep 2026
Bought (12 mo)
$90.21K
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$82.29K
$82.29K on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 2 sales
Net
+$7.92K
+$90.21K against sales at will

By person

9 insiders · 7 transactions
0.2×

Laura E. Niklason holds only 0.2 times base salary in stock. $137.04K of shares against $633.61K in salary for 2025.

Salary from the company's own proxy. The shares are what Laura E. Niklason last reported holding, valued at $0.56, the price Common Stock was last bought or sold at on the open market here, on 14 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Sebelius Kathleen
Director
$50.00K (1)
+$50.00K
148,025
$83.19K
+259.2%
Parikh Shamik J
Chief Medical Officer
$41.15K (1) scheduled
−$41.15K
272,713
$153.26K
Sander Dale A.
CFO and Chief Corp. Dev. Off
$41.15K (1) scheduled
−$41.15K
307,813
$172.99K
+1,262%
Jones Keith Anthony
Director
$30.37K (3)
+$30.37K
50,000
$28.10K
Constantino Michael T.
Director
$9.84K (1)
+$9.84K
43,950
$24.70K
+255.9%
Niklason Laura E
President, CEO and Director
243,851
$137.04K
−93.9%
Scheessele William John
Chief Commercial Officer
22,018
$12.37K
+41.8%
Green Charles Bruce
Director
8,400
$4.72K
+250.0%
Dougan Brady W
Director
0
$0.00
−100.0%

No percentages here. This company's share count has moved by a factor of 2.2 over the window, from 125,859,496 to 277,798,105 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Parikh Shamik J
18 May 2026
Chief Medical Officer
Sold on a plan
45,887
$0.90
$41.15K
Sander Dale A.
18 May 2026
CFO and Chief Corp. Dev. Off
Sold on a plan
45,887
$0.90
$41.15K

What was left out

Form 4 filings counted 23
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 622,200
History held since 23 Sep 2020